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Introduction: Targeted temperature management improves outcome after cardiopulmonary resuscitation.
Reduction of resting energy expenditure might be one mode of action. The aim of this study was to correlate
resting energy expenditure and substrate oxidation rates with targeted temperature management at 33°C and
outcome in patients after cardiac arrest.
Methods: This prospective, observational cohort study was performed at the department of emergency medicine
and a medical intensive care unit of a university hospital. Patients after successful cardiopulmonary resuscitation
undergoing targeted temperature management at 33°C for 24 hours with subsequent rewarming to 36°C and
standardized sedation, analgesic and paralytic medication were included. Indirect calorimetry was performed five
times within 48 h after cardiac arrest. Measurements were correlated to outcome with repeated measures ANOVA,
linear and logistic regression analysis.
Results: In 25 patients resting energy expenditure decreased 20 (18 to 27) % at 33°C compared to 36°C without
differences between outcome groups (favourable vs. unfavourable: 25 (21 to 26) vs. 21 (16 to 26); P = 0.5). In
contrast to protein oxidation rate (favourable vs. unfavourable: 35 (11 to 68) g/day vs. 39 (7 to 75) g/day, P = 0.8)
patients with favourable outcome had a significantly higher fat oxidation rate (139 (104 to 171) g/day vs. 117
(70 to 139) g/day, P <0.05) and a significantly lower glucose oxidation rate (30 (−34 to 88) g/day vs. 77 (19 to 138)
g/day; P < 0.05) as compared to patients with unfavourable neurological outcome.
Conclusions: Targeted temperature management at 33°C after cardiac arrest reduces resting energy expenditure
by 20% compared to 36°C. Glucose and fat oxidation rates differ significantly between patients with favourable and
unfavourable neurological outcome.
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Targeted temperature management improves neuro-
logical outcome after cardiopulmonary resuscitation
(CPR) although the target temperature is matter of discus-
sion [1-3]. According to the guidelines of the European
Resuscitation Council and the American Heart Associ-
ation comatose patients resuscitated after cardiac arrest
should undergo therapeutic hypothermia with a target
temperature of 32 to 34°C for 24 hours [4,5].
Reduction of resting energy expenditure (REE) might
be one of the possible mechanisms underlying the pro-
tective effects of hypothermia provided that the counter-
regulatory mechanism of shivering is prevented by the
use of adequate medication [6,7]. The extent of REE
reduction is expected to be approximately 8% per °C [6,7].
In critically ill patients with fever, indirect calorimetry
showed REE reduction by 6 to 12% per °C using external
cooling [8,9]. In patients with traumatic brain injury no
reduction of REE was found below 35°C in contrast to
temperatures higher than 35°C [10].
Studies evaluating the influence of hypothermia on
substrate metabolism are rare. Most of them are animal
investigations or studies including non-sedated humans
and can, therefore, not be compared to the patients in
the present study [11-14].
Influence of therapeutic hypothermia on REE and sub-
strate metabolism in patients resuscitated after cardiac
arrest has not been investigated so far. Therefore, the
objective of this study was the investigation of the cor-
relation of REE and substrate oxidation rates with tem-
perature management at 33°C after cardiac arrest and
outcome.
Methods
This was a prospective, observational study using indir-
ect calorimetric assessments in patients undergoing
targeted temperature management at 33°C after cardiac
arrest as part of routine clinical care according to estab-
lished protocols in our Department of Emergency Medicine
[15]. The study was investigator-initiated and investigator-
driven. The study protocol conformed to the ethical
guidelines of the Declaration of Helsinki and was ap-
proved by the research ethics committee of the Medical
University of Vienna. According to the Austrian law the
Institutional Review Board for human studies approved
the protocol with an exception from informed consent
guidelines. None of the patients ended up having consent
refused by next of kin or recovered patients after they
awoke and were contacted.
The study was performed in the intensive care units
(ICUs) of the Department of Medicine III, Division of
Gastroenterology and Hepatology (Intensive Care Unit
13 h1) and the Department of Emergency Medicine at
the Medical University Hospital of Vienna.Patients were eligible for inclusion in the study if they
were older than 18 years of age and hospitalized within
6 hours after resuscitation from cardiac arrest.
Treatment
General
Patients were stabilized according to the treatment proto-
cols [15]. Standards of post-resuscitation care included
airway management and mechanical ventilation, treatment
of haemodynamic instabilities and arrhythmias, blood glu-
cose control and temperature control with a temperature
probe in the oesophagus. For every patient, age, sex, pre-
sumed cause of cardiac arrest, initial rhythm, duration of
CPR, comorbidities as well as laboratory data and medica-
tion were documented. Patients were followed up at 1, 6
and 12 months according to the Utstein Style using
the following scoring instruments: Glasgow coma scale
(GCS), cerebral performance category (CPC), and overall
performance category (OPC) [16].
Targeted temperature management
All patients were cooled using either Alsius Coolgard
3000™ (Zoll Medical Corporation., Chelmsford, MA, USA)
or Arctic Sun™ (Medivance, Inc., Louisville, CO, USA) with
the maximal cooling rate until the target core temperature
of 33°C. The cooling period lasted 24 hours and rewarming
was performed with a rate of 0.4°C/hour until a core tem-
perature of 36°C was reached.
Medication
All patients received sedation and analgesia with mid-
azolam and fentanyl as well as muscle paralysis with
rocuronium according to the therapeutic standards at
the Department of Emergency Medicine at the Medical
University of Vienna [15]. Depth of neuromuscular block-
ade was assessed using the TOF Watch™ SX (Organon
Medical Systems, Roseland, NJ, USA), which monitors
neuromuscular transmission during surgery or intensive
care by means of acceleromyography. Two electrodes are
placed above the ulnar nerve and the response to the
nerve stimulation is measured by using a small piezoelec-
trode acceleration transducer distally placed on the volar
side of the thumb. Four pulses are given and the measur-
ing is based upon a ratio of the amplitude of the fourth
evoked mechanical response to the first one. Sedation as
well as analgesic and paralytic medication was stopped
after rewarming at 36°C. Patients did not receive any
intravenous fluids containing dextrose during the study
period. As preferred, crystalloid Ringer lactate solution
was used. Some patients received isotonic saline solution.
Medications were dissolved or diluted using isotonic
saline or Ringer lactate solution or distilled water as
specified.
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Respiratory gas exchange was measured by computerized
open-circuit indirect calorimetry (Deltatrac™ II Metabolic
Monitor, Datex-Ohmeda Instruments, Helsinki, Finland)
as previously described [17,18]. Oxygen consumption and
carbon dioxide production were measured in 1-minute
intervals and the average of a 30-minute period was calcu-
lated. The paramagnetic oxygen sensor allows inspiratory
oxygen concentration up to 65% according to the manu-
facturer. Measurements were performed over a period of
1 hour. Data for further calculation were taken from the
second half of the measurement to assure steady state
conditions. Ventilator setting remained unchanged at least
half an hour before and during measurement. Patients did
not receive any form of caloric intake during the cooling
and rewarming period. They underwent an 8-hour fasting
period before the last calorimetry. To get an overview
about REE and substrate metabolism in the different
phases of post-resuscitation care (stable cooling phase,
passive rewarming, active rewarming, rewarmed stable
phase) indirect calorimetry was performed five times: 12
to 24 hours after achieving the target temperature of 33°C
(stable phase), during rewarming at a temperature of 34.5°C,
36°C, 36.5 to 37.5°C and 48 hours after cardiac arrest.
Sedation as well as analgesic and paralytic medication was
stopped after the measurement at 36°C.
Calculations
REE was expressed in kJ (Kcal)/day/m2 body surface
area. REE and oxidation rates for glucose, fat, and pro-
tein were calculated according to Ferrannini et al. [19].
It was assumed that for each 1 g nitrogen produced,
5.923 L oxygen were consumed and 4.754 L carbon
dioxide were produced (respiratory quotient for protein:
0.803) [20]. For calculation of urea nitrogen appearance
rates, changes in plasma urea concentration were taken
into account (measurement at the beginning and at the
end of each calorimetry) [21]. Urine production was
measured along with each calorimetric measurement.
Urinary urea nitrogen was measured colorimetrically [22].
The protein oxidation rate (g/d) was calculated as 6.25 ×
24-hour urea nitrogen production (g/d) [23].
Statistical analysis
Due to the pilot study character and data characteristics
we regarded a sample size of 25 patients to be feasible
and adequate to yielding sufficient precision of our
estimates. Continuous data are presented as median and
25 to 75% interquartile range (IQR) or mean ± standard
deviation as appropriate by distribution. Categorical data
are presented as count and relative frequency. Twenty-
five independent patients each contributed data from
five occasions defined by certain temperature levels. Ac-
cordingly, we treated data as panel data. Generally lineareffects were assessed across categories of temperature
and not across actual temperature on a °C scale.
To assess the influence of temperature on metabolic var-
iables we used linear random intercept models. The inde-
pendent variable was the metabolic variable, temperature
was modelled as linear variable, and the clustering variable
was a patient identifier. To assess a potential relation be-
tween metabolic variables and sedation we grouped data
according to temperature ≤36°C and >36°C, because sed-
ation protocols were linked to core temperature. We then
repeated the above regression by replacing temperature by
the dichotomous variable sedation.
To assess a potential association between metabolic vari-
ables and neurological outcome we calculated temperature
level-wise independent t tests adjusted for multiplicity by
the Bonferroni method. We then developed a logistic ran-
dom intercept model where favourable neurological out-
come was the independent variable, and each one of the
metabolic variables was entered as predictor, whilst allow-
ing for the panel structure of the data.
To assess the influence of norepinephrine dose on
metabolic variables we used linear random intercept
regression models with each metabolic variable as inde-
pendent variable, and norepinephrine therapy as predictor
allowing for clustering as described above. Likewise, we
investigated the influence of temperature on insulin dose
(U/hour) and serum creatinine (mg/dl). Both variables
were handled as continuous outcomes. We also tested for
an interaction of norepinephrine on the relation between
neurological outcome and metabolic variables.
To reassess our models we employed standard regres-
sion models using robust standard errors. Results from
both approaches were comparable for all calculations.
For data management we used Excel 2008 for Mac
(Microsoft Corporation, Redmond, WA, USA), for data
analysis we used Stata 9.0 for Mac (Stata Corp, College
Station, TX, USA). Generally a two-sided P value less
than 0.05 was considered statistically significant.
Results
Patient characteristics and outcome are given in Table 1.
The median sequential organ failure assessment (SOFA)
score was 10 (9.25 to 10.75) in patients with unfavourable
neurological outcome and 10 (9 to 11) in patients with
favourable neurological outcome. Targeted temperature
management was performed using surface cooling in 15
patients and intravascular cooling in 10 patients. We com-
pared C-reactive protein, fibrinogen and leukocyte count
as markers of inflammation as well as platelet count,
D-dimer, prothrombin time and activated partial throm-
boplastin time as markers of coagulation between the
patient groups undergoing different cooling methods.
No differences were observed between the two differ-
ent cooling methods (data not shown). Mean train-of-
Table 1 Patients’ characteristics and outcome data (n = 25)
Age (years) 61 ± 14
BMI (kg/m2) 26 ± 4
BSA (m2) 1.9 ± 0.2
Female – no (%) 6 (24)
Reason for CA – no (%)
MCI 15 (60)
Rhythm disorder 6 (24)
Others 4 (16)
Initial cardiac rhythm – no (%)
VF/VT 21 (84)
Asystole/PEA 4 (16)
CA to ROSC (min) 25 (14-32)
Neurological outcome at 12 months – no (%)
CPC 1–2 (favourable) 15 (60)
CPC 3–5 (unfavourable) 10 (40)
Survival – no (%) 16 (64)
Values are expressed as absolute numbers and percentage and as mean value ±
standard deviation or median with 25 to 75% quartiles. Others comprise one
intoxication with consecutive apnea, one high-voltage accident, one pulmonary
embolism and one unknown reason. BMI, body mass index; BSA, body surface
area; CA, cardiac arrest; MCI, myocardial infarction; VF, ventricular fibrillation; VT,
ventricular tachycardia; PEA, pulseless electric activity; ROSC, return of spontaneous
circulation; CPC, cerebral performance category.
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surements were performed. Two patients died after the
first measurement and in one patient indirect calorimetry
had to be stopped after the third measurement due to
technical failure of the monitor. In one patient the last
measurement could not be performed because of aFigure 1 Resting energy expenditure (REE) of all patients measured w
in kJ/m2 (kcal/m2) of body surface area (BSA)/day. A linear relation between
P <0.0001).fraction of inspired oxygen (FiO2) level of 100% due to
adult respiratory distress syndrome after aspiration. In
case of premature study termination collected data were
used for analysis until the patient left the study.
Time points of indirect calorimetric measurements
resulted in temperature categories of 1.5°C below 36°C
and temperature categories of 0.8°C above 36°C (as pre-
sented in Figures 1 and 2 and Table 2). The overall mean
oxygen consumption (VO2) was 241 ml/min with a range
from 125 to 662 ml/min over all measurements. Within
individuals the mean standard deviation (SD) was 13 ml/
min (5% of the mean) representing measurement variabil-
ity. Between individuals, SD was 68 ml/min on average
(28% of the mean) representing the variability be-
tween the patients. During the initial stable conditions
(with sedation, analgesics and paralysis at 33°C) vari-
ability was smaller: overall range 125 to 476 ml/min.
Within-individual SD was 9.00 ml/min (4.5% of the
mean). The between-individual SD was 52.13 ml/min
(26% of the mean).
Calorimetric measurements and substrate metabolism
of all patients are given in Table 2. Negative glucose
values reflect net gluconeogenesis whereas positive
values indicate glucose oxidation.
REE showed a reduction of 20 (18 to 27) % at 33°C
compared to 36°C without differences between outcome
groups (favourable vs. unfavourable: 25 (21 to 26) vs. 21
(16 to 26); P = 0.5) and a linear relation to temperature
alterations (297 kJ (71 kcal)/m2/°C category; P <0.0001)
(Figure 1).
Fat oxidation rate showed a temperature dependency
(10 g/day/°C category; P <0.0001), while glucose andith indirect calorimetry at the different temperatures. REE is given
REE and temperature was detected (297 kJ (71 kcal)/m2/°C category;
Figure 2 Changes in metabolic variables during the whole
study period assessed with indirect calorimetry at the defined
time points. Comparison of patients with favourable neurological
outcome (CPC 1 to 2) with unfavourable neurological outcome (CPC
3 to 5): black dots ●, favourable neurological outcome; grey squares
■, unfavourable neurological outcome, error bars indicate standard
deviation. (a) Linear regression of REE did not show a difference
between patients with favourable and unfavourable neurological
outcome (P = 0.2). (b) Linear regression of fat oxidation rates
revealed a significant difference between patients with favourable
and unfavourable neurological outcome (P <0.05). (c) Linear
regression of glucose oxidation rates revealed a significant difference
between patients with favourable and unfavourable neurological
outcome (P <0.05). (d) Linear regression of protein oxidation rates
did not show a difference between patients with favourable and
unfavourable neurological outcome (P = 0.8). CPC, cerebral
performance category; REE, resting energy expenditure.
Holzinger et al. Critical Care  (2015) 19:128 Page 5 of 9protein oxidation rates were not significantly dependent
from temperature (P = 0.07 or P = 0.06, respectively).
In contrast to protein oxidation rate (favourable vs.
unfavourable outcome: 35 (11 to 68) g/day vs. 39 (7 to 75)
g/day, P = 0.8) patients with favourable outcome had a sig-
nificantly higher fat oxidation rate (139 (104 to 171) g/day
vs. 117 (70 to 139) g/day, P <0.05) and a significantly
lower glucose oxidation rate (30 (−34 to 88) g/day vs. 77
(19 to 138) g/day; P <0.05) as compared to patients with
unfavourable neurological outcome (Figure 2).
REE was not associated with neurological outcome
(odds ratio (OR) 0.88, 95% confidence interval (CI) 0.63
to 1.22 of favourable neurological outcome for each unit
increase in REE quartile, P = 0.4; Figure 2). Probability of
unfavourable neurological outcome increased by 69%
(OR 1.69, 95% CI 1.15 to 2.49; P <0.01) with every increase
of glucose oxidation rate from one quartile to the next.
Probability of unfavourable neurological outcome de-
creased by 38% (OR 0.62, 95% CI 0.44 to 0.87; P <0.01)
with every increase of fat oxidation rate from one quartile
to the next.
For all patients dosage of sedation and analgesic medi-
cation (midazolam, fentanyl), neuromuscular blocker
(rocuronium) and norepinephrine as well as insulin at
the different measurement points is given in the elec-
tronic supplementary file (Table S1 in Additional file 1).
One patient received dobutamine during the rewarming
period (measurement 2, 3 and 4). Another patient re-
ceived levosimendan during the first two measurements.
Although both medications might influence metabolism,
subgroup analysis was not possible due to the small
number of patients.
Insulin therapy was not associated with outcome (P =
0.3), REE (P = 0.7) or substrate oxidation rates (glucose:
P = 0.2; fat: P = 0.9; protein: P = 0.7).
Sedation, analgesia and neuromuscular blockade (NMB)
rates were strongly associated with REE reduction; (967 kJ
(231 kcal)/day/m2 (95% CI 181 (758) to 280 (1,172);
Table 2 Substrate metabolism of all patients at different calorimetric measurement
Points of measurement (°C)
33 34.5 36 36.8 37.6
RQ 0.72 (0.69-0.83) 0.76 (0.72-0.82) 0.76 (0.74-0.79) 0.75 (0.72-0.79) 0.75 (0.73-0.78)
VO2 (ml/min) 187 (147-220) 215 (179-248) 243 (191-266) 264 (221-313) 259 (246-311)
VCO2 (ml/min) 136 (122-151) 162 (138-187) 185 (148-199) 193 (173-232) 198 (189-234)
pH 7.36 (7.29-7.41) 7.36 (7.31-7.40) 7.37 (7.32-7.40) 7.35 (7.26-7.40) 7.34 (7.29-7.43)
Lactate (mmol/l) 1.4 (1.0-2.0) 1.4 (1.0-1.9) 1.2 (0.9-1.7) 1.1 (0.9-1.4) 1.0 (0.9-1.6)
UNP (g/d) 6.1 (2.3-9.1) 4.2 (1.2-12.1) 3.4 (1.9-8.8) 9.7 (4.7-22.1) 4.4 (0.5-16.3)
Glucose (g/d) −5 (−50-92) 79 (−13-113) 67 (14-106) 36 (−27-86) 50 (5-105)
Fat (g/d) 125 (55-154) 118 (69-137) 128 (109-164) 153 (106-175) 140 (119-178)
Protein (g/d) 38.3 (14.2-57.1) 25.9 (7.7-75.3) 21.4 (11.9-55.3) 60.4 (29.6-137.8) 27.5 (2.9-101.9)
Creatinine (mg/dl) 0.96 (0.65-1.05) 0.87 (0.70-0.99) 0.92 (0.79-1.05) 0.91 (0.73-1.07) 0.98 (0.76-1.14)
Negative glucose values reflect net gluconeogenesis whereas positive values indicate glucose oxidation. Additionally arterial blood ph and lactate are given as
marker of aerobe metabolism and creatinine as marker of renal function. Values are expressed as median with 25 to 75% quartiles. RQ, respiratory quotient; VO2,
oxygen consumption; VCO2, carbon dioxide production; UNP, urea nitrogen production.
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by 34 g/d (95% CI 14 to 54; P <0.01) during sed-
ation. Glucose oxidation rate (P = 0.9) and protein
oxidation (P = 0.06) were not significantly associated
with sedation.
Even though we did not find an association between
norepinephrine therapy and REE (P = 0.7) or protein
oxidation rate (P = 0.6), norepinephrine therapy was as-
sociated with increased glucose oxidation rate (P <0.05)
and reduced fat oxidation rate (P <0.05). However, there
was no significant interaction of norepinephrine on the
relation between neurological outcome and metabolic
variables. Norepinephrine therapy was not associated
with outcome (P = 0.7).
Temperature was not associated with insulin therapy
(P = 0.6) or serum creatinine levels (P = 0.8). We did not
find an association between outcome and serum creatin-
ine levels (P = 0.6).
Dosage of all administered medications and blood glu-
cose values at different calorimetric measurements are
given in the Table S1 in Additional file 1 for all patients.
Discussion
Our study showed that in patients after cardiac arrest
and successful return of spontaneous circulation undergo-
ing targeted temperature management at 33°C REE was
reduced (20% (18 to 27%)) compared to 36°C with a linear
relation to temperature alterations but without differences
between outcome groups. Besides temperature, sedation,
analgesia and NMB were associated with a REE reduction.
Only fat oxidation rate was associated with temperature,
sedation and analgesia. Glucose oxidation rates and fat
oxidation rates were significantly different between pa-
tients with favourable and unfavourable neurological
outcome. An interaction between norepinephrine therapy,
neurological outcome and metabolic variables could beexcluded. Use of medication (sedatives, analgetics, neuro-
muscular blockers, insulin and norepinephrine) was not
different between patients with favourable and unfavour-
able neurological outcome.
The effect of cooling on REE has already been described.
In hyperthermic patients cooling was able to reduce REE
between 6 and 12% per 1°C temperature reduction de-
pending on sedation, analgesia and NMB [7,8]. In neuro-
surgical patients, a significant reduction of REE by cooling
was only detectable above a temperature of 35°C using
sedation and neuromuscular blockers [10]. Generally, a re-
duction of 6 to 9% of REE per 1°C decrease in temperature
is accepted [6,7]. Our study showed a 6.6% reduction of
REE per 1°C decrease at temperatures below 36°C.
A limitation of our study is that effects of sedation,
analgesia, NMB and hypothermia cannot be separated
due to the study design. All indirect calorimetric mea-
surements at 36°C and below were performed with con-
comitant sedation, analgesia and NMB.
In surgical ICU patients increasing Ramsay sedation
scale using midazolam resulted in a significantly decreased
REE and oxygen consumption [24]. NMB in combination
with controlled mechanical ventilation was able to reduce
oxygen consumption by approximately 20% [25]. In critic-
ally ill children NMB was able to reduce REE by approxi-
mately 10% [26]. We found a median reduction of REE of
20% in our study in adult patients after cardiac arrest at
33°C. Our data suggest that effects of sedation, analgesia,
NMB and hypothermia on REE might not be additive.
This assumption is supported by another study, which
showed that in normothermic patients sedation has a
major effect on REE; however, in sedated patients tempe-
rature was the main determinant of REE [27].
Due to the chosen medication regimen with continu-
ous midazolam, fentanyl and rocuronium administration
during the cooling and the passive rewarming period the
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REE, can be disregarded [28,29].
In our study, patients after cardiac arrest and return of
spontaneous circulation (ROSC) with favourable neuro-
logical outcome had significantly different fat and glucose
oxidation rates compared to patients with unfavourable
neurological outcome. An increase in quartiles of fat oxi-
dation rate was associated with favourable and an increase
in quartiles of glucose oxidation was associated with un-
favourable neurological outcome.
Data on substrate metabolism during hypoxia and
hypothermia were only available from animal experi-
ments or experiments with healthy subjects. In six
healthy males resting at a temperature of 5°C, free fatty
acid turnover, as well as lipid oxidation and carbohy-
drate oxidation remarkably increased, however this in-
crease was accompanied by a significant increase in the
REE [11]. The increase of REE in this experiment is pre-
dominantly caused by shivering and thus is not compar-
able to our analysis.
Hypoxia seems to be associated with remarkable
changes in substrate utilization especially in the brain. In
cooled anaesthesized dogs, hypoxic conditions increased
glucose utilization in the brain [12]. Further animal
experiments showed that glucose transporter (GLUT) 3
expression increases up to nine times both in the affected
and non-affected neurons after 48 hours of rat brains
under ischaemic conditions [13]. This finding is in accord-
ance with data from a rat model of traumatic brain injury,
which showed a 300% increase of GLUT 3 expression up
to 48 hours after the event [14]. In traumatic brain injury,
a remarkable increase in glucose utilization of the whole
brain (hyperglycolysis) can be found up to 7 days after the
trauma [30,31]. We therefore hypothesize that in patients
with unfavourable neurological outcome increased cere-
bral glucose utilization was present due to severe hypoxia-
induced brain injury during cardiac arrest. We assume
that this increase accounted for the elevated glucose oxi-
dation rates measured by indirect calorimetry. Since brain
glucose utilization normally accounts for 25% of whole
body glucose metabolism [32], changes in glucose oxida-
tion rates of the brain are obviously detectable by indirect
calorimetry evaluating whole body substrate metabolism.
We cannot rule out influence of other post-cardiac arrest
organ injury, especially liver and kidney, on REE and sub-
strate metabolism in our study patients [33,34]. However
apart from brain injury, other organ injury seemed to be
equally distributed in both patient groups and, therefore,
is improbable of having caused the effect shown in our
study.
Norepinephrine therapy was significantly associated
with glucose and fat oxidation rates but did not interact
with the relation between neurological outcome and
metabolic values and was not associated with outcomein the present study. Influence of norepinephrine on fat
utilization has already been shown before in healthy sub-
jects [35].
Although hypothermia is associated with increased in-
sulin resistance and glucose intolerance, insulin therapy
was not associated with temperature in our study [6,36].
Insulin was neither associated with REE nor with sub-
strate oxidation rates. Influence of insulin on substrate
oxidation rates and energy expenditure seems to be lim-
ited [37,38].
A further limitation of our study is the technique of
indirect calorimetry itself, which has the advantage of
being non-invasive, however, is prone to multiple errors.
Although, measurements were performed according to
the manufacturer’s instructions and with greatest dili-
gence, errors influencing our results cannot be fully ex-
cluded [39]. Using indirect calorimetry, only whole body
net balances of substrate metabolism can be described
without knowledge of localized substrate oxidation or
biosynthesis rates. We can rule out bias of anaerobic
metabolic pathways in a substantial way because lactate
levels were in the normal range throughout the study
period. That is why measurements started in the second
half of the 24-hour cooling period, in order to have
already achieved stabilized conditions, without anaerobic
metabolism.
Besides the small number of patients included, a major
limitation of this study is the substantial variability of
the measurements of substrate metabolism themselves.
The factors that impact substrate metabolism - including
the specific blend of organ failures, host global and
organ-specific inflammation and function - are multitu-
dinous. Accordingly, we cannot discount the possibility
of confounding by variables not measured in this study
like interleukin levels or organ-specific substrate metab-
olism, but our study nonetheless raises an interesting
hypothesis for future studies that might control for the
most important confounders. Results have to be repro-
duced and further investigation is necessary to elucidate
pathophysiological actions during the post-cardiac arrest
period resulting in detectable metabolic differences be-
tween patients with favourable and unfavourable neuro-
logical outcome.
Conclusions
Targeted temperature management at 33°C after cardiac
arrest reduces REE by 20% with a linear relation to
temperature variations. Only fat oxidation rate was
temperature dependent. A significant difference in glu-
cose and fat oxidation rates was found between patients
with favourable and unfavourable neurological outcome.
An increase of fat oxidation rate and a decrease of
glucose oxidation rate were associated with favourable
outcome.
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 Resting energy expenditure is reduced in patients
undergoing targeted temperature management after
cardiac arrest irrespective of outcome.
 A difference in fat and glucose oxidation rates can
be found between patients with favourable and
unfavourable neurological outcome.
Additional file
Additional file 1: Mean dosage of medications given to patients
with favourable and unfavourable neurological outcome and mean
blood glucose at different measurements. All medications are given
as median and interquartile range. Blood glucose is given as mean ± SD.
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VCO2: carbon dioxide production; VF: ventricular fibrillation; VO2: oxygen
consumption; VT: ventricular tachycardia.
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